By Steve Usdin, Washington Editor The fight against COVID-19 is far from finished, but victory is close enough to start considering how...

COVID-19 long-hauler treatment trials will likely rely on established endpoints and trial design features used in other conditions, and...

Long-term COVID-19 vaccine durability has become less of an endgame since it has become increasingly likely additional shots will be...

COVID-19 didn’t disappear with summer temperatures, it just shifted locations and demographics. Now, with both autumn and flu season fast...

Treatments for COVID-19 may be focusing on at the wrong elements of the disease, according to physicians analyzing results from Bergamo,...

Fate Therapeutics’ (NASDAQ:FATE) and Celyad’s (NASDAQ:CYAD) natural killer (NK) cell biology-focused cell therapies could overcome cell...

Aurinia Pharmaceutical’s (NASDAQ:AUPH) voclosporin has potential long-term nephrotoxicity concerns that could preclude widespread...

Early-phase melanoma trials testing microbiome approaches that leverage a broad- spectrum antibiotic or microbiome monotherapy before...

Evofem’s (NASDAQ:EVFM) contraceptive gel Amphora leaves experts needing detailed 12-month efficacy data despite available Phase III...

By Sandi Wong, Assistant Editor "THERE IS A HUGH DIFFERENCE BETWEEN THE POSSIBILITY THAT A VACCINE WILL SENSITIZE A SUSCEPTIBLE,...